TSO3 Simplifies Sterilization of Complete Heavy-Duty, Battery-Powered Orthopedic Instrument Sets

Company Offers Single-Cycle Solution that can
Replace Steam and Legacy Low-Temperature Sterilization Practices
 
QUÉBEC CITY, July 25, 2016 - TSO3 Inc. (TSX:TOS.TO - News) ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, has completed sterile efficacy validation for multiple, heavy-duty battery-powered orthopedic instrument sets in a single sterilization cycle of the Company's STERIZONE® VP4 Sterilizer.
 
These large and heavy instrument sets consist of batteries, attachments, handpieces and inserts. The instrument sets are often "split up" and sterilized in multiple steam cycles or a combination of the traditional steam and legacy low-temperature sterilization (LTS) systems. The STERIZONE® VP4 Sterilizer has been validated to process complete instrument sets in a single cycle -- allowing the instruments to travel together within a hospital and arrive sterile at the operating room together.  This means faster turn-around times, simpler instrument management and cost-effective reprocessing when compared to traditional steam and LTS systems.
Read more: TSO3 Inc ( TOS )

TSO3 Prepares for European Product Launch

Company Pursues Prion Inactivation Claims and Expands Portfolio with Double-Door Option for Revolutionary STERIZONE® VP4 Sterilizer
 
QUÉBEC CITY, July 18, 2016  - TSO3 Inc. (TOS.TO) (« TSO3 » or the « Company »), an innovator in sterilization technology for medical devices in healthcare settings, today announced a series of initiatives in support of a planned European launch of the Company's STERIZONE® VP4 Sterilizer this year.
 
The Company has initiated studies in France in support of obtaining Prion inactivation claims for that market. In addition, the Company has completed development of a double door, or "pass-through", option for the STERIZONE® VP4 Sterilizer which is highly desirable in many European markets.
Read more: TSO3 Inc ( TOS )

BioLife Solutions Executes 10 Year Supply Agreement with Kite Pharma for CryoStor® Use in CAR T Cell Therapies

BOTHELL, Wash., July 11, 2016  -- BioLife Solutions, Inc. (BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage andcryopreservation freeze media and a related cloud hosted biologistics cold chain management app forsmart shippers ("BioLife" or the "Company"), today announced that it has entered into a ten year supply agreement with Kite Pharma, a leading developer of chimeric antigen receptor (CAR) and T cell receptor (TCR) products for various cancers.
 
The agreement provides for Kite's supply of BioLife's CryoStor clinical grade freeze media for cells and tissues, which is embedded in Kite's manufacturing process for KTE-C19, a CAR T cell therapy currently in four clinical trials for various cancers.
 
Marc Better, Vice President, Product Sciences at Kite Pharma, noted, "Over the last several years we have worked to qualify and adopt CryoStor in our clinical manufacturing process. We are now securing long term supply continuity for this reagent as our cell therapy product candidate continues to progress through multiple clinical trials."
Read more: BioLife Solutions Inc ( BLFS )

University of Chicago Medicine Creating High-Tech Arrhythmia Technology Suite with Stereotaxis Niobe® ES System

ST. LOUIS, July 13, 2016 -- Stereotaxis, Inc. (STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the University of Chicago Medicine will implement the Company’s Niobe® ES remote magnetic navigation system as part of its vision to create a cutting-edge arrhythmia technology suite. The University of Chicago Medicine is one of the nation's leading academic medical institutions, consistently ranked among the best hospitals in the nation by U.S. News & World Report. The Center for Arrhythmia Care at the University of Chicago Medicine, led by renowned cardiologist Dr. Roderick Tung, director of the cardiac electrophysiology program, is one of the busiest university-based heart rhythm programs in the Chicago area.
 
“The Niobe system is perhaps the most revolutionary invention in the field of cardiac ablation, enabling remote anatomic mapping of electrical currents and eradication of difficult-to-reach arrhythmias with unparalleled safety and pinpoint precision,” said Tung. “Our acquisition of Stereotaxis’ latest generation remote magnetic navigation platform will enhance a highly respected electrophysiology (EP) program that is regarded as a global leader in ablation therapy, research and education, especially in the treatment of ventricular tachycardia (VT), and will greatly improve patients’ lives.”
Read more: Stereotaxis Inc ( STXS )

Stereotaxis Niobe® ES System Installed at Texas Children’s Hospital

First pediatric institution in U.S. to offer magnetic navigation technology for cardiac ablation
 
ST. LOUIS, July 08, 2016 -- Stereotaxis, Inc. (STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that Texas Children’s Hospital in Houston has installed the Company’s Niobe® ES system, making it the only pediatric hospital in the country to offer the latest generation remote magnetic navigation platform for ablation procedures. Texas Children’s is recognized as one of the top children’s hospitals in the nation, ranked #2 nationally in cardiology and heart surgery by U.S. News & World Report.
 
“We are privileged to provide this cutting-edge treatment for our patients with arrhythmias in whom cardiac ablations are deemed necessary,” said Dr. Jeffrey Kim, director of the Arrhythmia and Pacing Service at Texas Children’s. “With the Niobesystem, we can more quickly and aggressively target and ablate abnormal electrical impulses in young children and patients with structurally complex anatomy. This is an important tool in our armamentarium for this highly specialized procedure and undoubtedly advances our approach to pediatric cardiac rhythm management.”
Read more: Stereotaxis Inc ( STXS )

Videos / Webinars

View all videos

Pepperstone | Metatrader 4 Forex Broker